Switch theme
Sign up to access all valuation multiples
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
2003
5.3K+
LTM Revenue $2.7B
LTM EBITDA $789M
$6.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Globus Medical has a last 12-month revenue (LTM) of $2.7B and a last 12-month EBITDA of $789M.
In the most recent fiscal year, Globus Medical achieved revenue of $2.5B and an EBITDA of $474M.
Globus Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Globus Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.7B | XXX | $2.5B | XXX | XXX | XXX |
| Gross Profit | $1.8B | XXX | $1.5B | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $789M | XXX | $474M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $579M | XXX | $220M | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $433M | XXX | $103M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 4% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Globus Medical's stock price is $53.
Globus Medical has current market cap of $7.2B, and EV of $6.9B.
See Globus Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.9B | $7.2B | XXX | XXX | XXX | XXX | $3.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Globus Medical has market cap of $7.2B and EV of $6.9B.
Globus Medical's trades at 2.7x EV/Revenue multiple, and 14.5x EV/EBITDA.
Equity research analysts estimate Globus Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Globus Medical has a P/E ratio of 16.7x.
See valuation multiples for Globus Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.2B | XXX | $7.2B | XXX | XXX | XXX |
| EV (current) | $6.9B | XXX | $6.9B | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 8.7x | XXX | 14.5x | XXX | XXX | XXX |
| EV/EBIT | 11.9x | XXX | 31.3x | XXX | XXX | XXX |
| EV/Gross Profit | 3.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 16.7x | XXX | 70.3x | XXX | XXX | XXX |
| EV/FCF | 16.3x | XXX | 16.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGlobus Medical's last 12 month revenue growth is 10%
Globus Medical's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Globus Medical's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Globus Medical's rule of X is 54% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Globus Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 54% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 54% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 50% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Globus Medical acquired XXX companies to date.
Last acquisition by Globus Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Globus Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Globus Medical founded? | Globus Medical was founded in 2003. |
| Where is Globus Medical headquartered? | Globus Medical is headquartered in United States of America. |
| How many employees does Globus Medical have? | As of today, Globus Medical has 5.3K+ employees. |
| Who is the CEO of Globus Medical? | Globus Medical's CEO is Mr. Keith W. Pfeil. |
| Is Globus Medical publicy listed? | Yes, Globus Medical is a public company listed on NYS. |
| What is the stock symbol of Globus Medical? | Globus Medical trades under GMED ticker. |
| When did Globus Medical go public? | Globus Medical went public in 2012. |
| Who are competitors of Globus Medical? | Similar companies to Globus Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Globus Medical? | Globus Medical's current market cap is $7.2B |
| What is the current revenue of Globus Medical? | Globus Medical's last 12 months revenue is $2.7B. |
| What is the current revenue growth of Globus Medical? | Globus Medical revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Globus Medical? | Current revenue multiple of Globus Medical is 2.5x. |
| Is Globus Medical profitable? | Yes, Globus Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Globus Medical? | Globus Medical's last 12 months EBITDA is $789M. |
| What is Globus Medical's EBITDA margin? | Globus Medical's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Globus Medical? | Current EBITDA multiple of Globus Medical is 8.7x. |
| What is the current FCF of Globus Medical? | Globus Medical's last 12 months FCF is $420M. |
| What is Globus Medical's FCF margin? | Globus Medical's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Globus Medical? | Current FCF multiple of Globus Medical is 16.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
